Pediatric eosinophilic gastrointenstinal disease First successful treatment with Dupilumab

Keck, J., Krahl, A., Mueller, A. M., Foerster, N. and Gerner, P. . Pediatric eosinophilic gastrointenstinal disease First successful treatment with Dupilumab. Mon.schr. Kinderheilkd.. NEW YORK: SPRINGER. ISSN 1433-0474

Full text not available from this repository.

DOI:10.1007/s00112-020-01031-6

Abstract

Eosinophilic gastrointestinal diseases are local inflammatory conditions of the upper and lower gastrointestinal tract. They are triggered by an abnormal allergen-mediated immune response and are increasingly already being diagnosed in childhood and adolescence. In case of a lack of response to standard treatment regimens, quality of life can be severely impaired due to difficulty in swallowing, food impaction, abdominal pain and diarrhea. We report on the first adolescent patient with severe symptoms of eosinophilic gastroenteropathy nonresponsive to the known standard treatment regimens, who was successfully treated with dupilumab. Dupilumab is a monoclonal human antibody against the IL-4/IL-13 pathway. So far, it has been successfully used in the treatment of moderate to severe atopic dermatitis and allergic asthma. The first phase II randomized controlled trial for the treatment of eosinophilic esophagitis in adults was recently published. The intention of this case report is to point to the use of dupilumab as a treatment option for severe eosinophilic gastrointestinal disease also in pediatric patients.

Item Type:

Journal Article

Creators:

Creators	Email	ORCID	ORCID Put Code
Keck, J.	UNSPECIFIED	UNSPECIFIED	UNSPECIFIED
Krahl, A.	UNSPECIFIED	UNSPECIFIED	UNSPECIFIED
Mueller, A. M.	UNSPECIFIED	UNSPECIFIED	UNSPECIFIED
Foerster, N.	UNSPECIFIED	UNSPECIFIED	UNSPECIFIED
Gerner, P.	UNSPECIFIED	UNSPECIFIED	UNSPECIFIED